HRP20211708T1 - Antagonisti lpa - Google Patents
Antagonisti lpa Download PDFInfo
- Publication number
- HRP20211708T1 HRP20211708T1 HRP20211708TT HRP20211708T HRP20211708T1 HR P20211708 T1 HRP20211708 T1 HR P20211708T1 HR P20211708T T HRP20211708T T HR P20211708TT HR P20211708 T HRP20211708 T HR P20211708T HR P20211708 T1 HRP20211708 T1 HR P20211708T1
- Authority
- HR
- Croatia
- Prior art keywords
- independently selected
- image
- alkyl
- pharmaceutical composition
- oral pharmaceutical
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 15
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
- C07C62/10—Saturated compounds containing ether groups, groups, groups, or groups with a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Claims (14)
1. Oralna farmaceutska kompozicija koja sadrži spoj formule (III):
[image]
ili enantiomer, dijastereomer, stereoizomer, farmaceutski prihvatljivu sol istog, pri čemu
R2 je nezavisno odabrano od CH3 i CD3;
R13 je nezavisno odabrano od H i C1-4 alkila;
R3 je nezavisno odabrano od H i C1-4 alkila;
R4 je nezavisno odabrano od C1-6 alkila supstituiranog sa 1-3 R9, -(CR7R7)r-C3-6 cikloalkila supstituiranog sa 1-3 R8, i -(CR7R7)r-arila supstituiranog sa 1-3 R8;
R5 je nezavisno odabrano od H, F, Cl, CN i C1-4 alkila; pod uvjetom da jedno od R5 je H;
R6 je
[image]
R7 je nezavisno odabrano od H, C1-4 alkila, i C3-6 cikloalkila; ili R7 i R7, zajedno sa atomom ugljika za koji su oba vezana, formiraju C3-6 cikloalkilni prsten;
R8 je nezavisno odabrano od H, C1-6 alkila supstituiranog sa 1-5 R9, C3-6 cikloalkila, F, Cl, Br, CN, =O, i COOH;
R9 je nezavisno odabrano od H, F, Cl, NH2, OH, OC1-5alkila, C1-5alkila, C3-6 cikloalkila, i fenila pri čemu kada R9 je Cl, NH2 ili OH ono nije supstituirano na Ci alkila za koji je vezano;
R10 je nezavisno odabrano od H, D, C1-4 alkila, i F;
R11 je nezavisno odabrano od CN, -C(=O)R12, i tetrazolila;
R12 je nezavisno odabrano od OH, OC1-4 alkila, NH2, i NHSO2C1-4alki; i r je nezavisno odabrano od nula, 1, 2, 3, i 4;
i farmaceutski prihvatljiv nosač ili razblaživač.
2. Oralna farmaceutska kompozicija iz patentnog zahtjeva 1, pri čemu navedeni spoj ima formulu (IV):
[image]
ili enantiomer, dijastereomer, stereoizomer, farmaceutski prihvatljiva sol istog, pri čemu
R2 je nezavisno odabrano od CH3 i CD3;
R13 je nezavisno odabrano od H i C1-4 alkila;
R3 je nezavisno odabrano od H i C1-4 alkila;
R4 je nezavisno odabrano od C1-6 alkila,
[image]
[image]
R5 je nezavisno odabrano od H, F, Cl, i C1-4 alkila; pod uvjetom da jedno od R5 je H;
R7 je nezavisno odabrano od H, C1-4 alkila, i C3-6 cikloalkila;
R8 je nezavisno odabrano od H, C1-6 alkila supstituiranog sa 1-5 R9, C3-6 cikloalkila, F, Cl, Br, CN, =O, i COOH;
R9 je nezavisno odabrano od H, F, Cl, NH2, OH, OC1-5alkila, C1-5alkila, C3-6 cikloalkila, i fenila pri čemu kada R9 je Cl, NH2 ili OH ono nije supstituirano na Ci alkila za koji je vezano;
R10 je nezavisno odabrano od H, D, C1-4 alkila, i F;
R11 je nezavisno odabrano od CN, -C(=O)R12, i
[image]
i
R12 je nezavisno odabrano od OH i NHSO2C1-4alki.
3. Oralna farmaceutska kompozicija iz patentnog zahtjeva 3, pri čemu
R4 je nezavisno odabrano od
[image]
[image]
[image]
[image]
[image]
i
R8 je nezavisno odabrano od H, F, Cl, Br, CN, i C1-4 alkila.
4. Oralna farmaceutska kompozicija iz patentnog zahtjeva 3, pri čemu navedeni spoj ima formulu (V):
[image]
ili enantiomer, dijastereomer, stereoizomer, farmaceutski prihvatljiva sol istog, pri čemu
R2 je nezavisno odabrano od CH3 i CD3;
R13 je nezavisno odabrano od H i CH3;
R3 je nezavisno odabrano od H i CH3;
R4 je nezavisno odabrano od
[image]
[image]
[image]
[image]
[image]
i
R5 je nezavisno odabrano od H, F, i C1-4 alkila;
R8 je nezavisno odabrano od H, F, Cl, Br, CN, i C1-4 alkila;
R10 je nezavisno odabrano od H, D, i F; i
R11 je nezavisno odabrano od -C(=O)OH, i -C(=O)NHSO2Me.
5. Oralna farmaceutska kompozicija iz patentnog zahtjeva 3, pri čemu navedeni spoj ima formulu (VI):
[image]
ili enantiomer, dijastereomer, stereoizomer, farmaceutski prihvatljiva sol istog, pri čemu
R2 je nezavisno odabrano od CH3 i CD3;
R13 je nezavisno odabrano od H i CH3;
R3 je nezavisno odabrano od H i CH3;
R4 je nezavisno odabrano od
[image]
[image]
[image]
R5 je nezavisno odabrano od H i CH3; i
R8 je nezavisno odabrano od H, F, Cl, Br, CN, i C1-4 alkila.
6. Oralna farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu navedeni spoj ima formulu:
[image]
enantiomer, dijastereomer, stereoizomer, ili farmaceutski prihvatljiva sol istog.
7. Oralna farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu navedeni spoj ima formulu:
[image]
enantiomer, dijastereomer, stereoizomer, ili farmaceutski prihvatljiva sol istog.
8. Oralna farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu navedeni spoj ima formulu:
[image]
enantiomer, dijastereomer, stereoizomer, ili farmaceutski prihvatljiva sol istog.
9. Oralna farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu navedeni spoj ima formulu:
[image]
enantiomer, dijastereomer, stereoizomer, ili farmaceutski prihvatljiva sol istog.
10. Oralna farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu navedeni spoj ima formulu:
[image]
enantiomer, dijastereomer, stereoizomer, ili farmaceutski prihvatljiva sol istog.
11. Oralna farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10 za primjenu u terapiji.
12. Oralna farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10 za primjenu u liječenju ili prevenciji fibroze organa kod sisavca koji ima potrebu za istim.
13. Oralna farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10 za primjenu u liječenju fibroze pluća (idiopatske fibroze pluća), astme, kronične opstruktivne bolesti pluća (HOBP), renalne fibroze, akutne povrede bubrega, kronične bubrežne bolesti, fibroze jetre (nealkoholnog steatohepatitisa), fibroze kože, fibroze crijeva, raka dojke, raka gušterače, raka jajnika, raka prostate, glioblastoma, raka kostiju, raka debelog crijeva, raka mokraćnog mjehura, raka glave i vrata, melanoma, multiplog mijeloma, kronične limfocitne leukemije, kancerogene boli, metastaze tumora, odbacivanja transplantiranih organa, skleroderme, okularne fibroze, degeneracije makule povezane sa starošću (AMD), dijabetičke retinopatije, kolagene vaskularne bolesti, ateroskleroze, Rejnoovog fenomena (Raynaud’s phenomenon) ili neuropatske boli kod sisavaca koji imaju potrebu za tim.
14. Oralna farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-10 za primjenu u liječenju idiopatske plućne fibroze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352792P | 2016-06-21 | 2016-06-21 | |
| EP20154651.2A EP3666771B1 (en) | 2016-06-21 | 2017-06-20 | Lpa antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20211708T1 true HRP20211708T1 (hr) | 2022-02-04 |
| HRP20211708T8 HRP20211708T8 (hr) | 2022-03-04 |
Family
ID=59258388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211708TT HRP20211708T8 (hr) | 2016-06-21 | 2017-06-20 | Antagonisti lpa |
| HRP20200586TT HRP20200586T1 (hr) | 2016-06-21 | 2020-04-13 | Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200586TT HRP20200586T1 (hr) | 2016-06-21 | 2020-04-13 | Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa |
Country Status (32)
| Country | Link |
|---|---|
| US (7) | US10071078B2 (hr) |
| EP (2) | EP3472148B1 (hr) |
| JP (2) | JP7073281B2 (hr) |
| KR (2) | KR102377340B1 (hr) |
| CN (2) | CN114601830A (hr) |
| AR (1) | AR108838A1 (hr) |
| AU (2) | AU2017281439B2 (hr) |
| BR (1) | BR112018076558A2 (hr) |
| CA (1) | CA3029202C (hr) |
| CL (1) | CL2018003708A1 (hr) |
| CO (1) | CO2019000471A2 (hr) |
| CY (2) | CY1123443T1 (hr) |
| DK (2) | DK3472148T3 (hr) |
| EA (1) | EA037585B1 (hr) |
| ES (2) | ES2895385T3 (hr) |
| HR (2) | HRP20211708T8 (hr) |
| HU (2) | HUE049944T2 (hr) |
| IL (1) | IL263767B (hr) |
| LT (2) | LT3472148T (hr) |
| ME (1) | ME03804B (hr) |
| MX (1) | MX2018015563A (hr) |
| MY (1) | MY195782A (hr) |
| PE (1) | PE20190211A1 (hr) |
| PL (2) | PL3666771T3 (hr) |
| PT (2) | PT3666771T (hr) |
| RS (2) | RS62524B1 (hr) |
| SG (1) | SG11201811321TA (hr) |
| SI (2) | SI3666771T1 (hr) |
| TW (2) | TWI757128B (hr) |
| UY (1) | UY37302A (hr) |
| WO (1) | WO2017223016A1 (hr) |
| ZA (1) | ZA201808580B (hr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| WO2019126099A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| JP7212047B2 (ja) * | 2017-12-19 | 2023-01-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126098A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| CN112074515A (zh) | 2017-12-19 | 2020-12-11 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| JP7301839B2 (ja) * | 2017-12-19 | 2023-07-03 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 |
| WO2019126089A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| CA3085561A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| PT3710438T (pt) * | 2017-12-19 | 2021-11-22 | Bristol Myers Squibb Co | Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa |
| KR20200100713A (ko) * | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸 |
| ES2948793T3 (es) * | 2018-09-18 | 2023-09-19 | Bristol Myers Squibb Co | Acidos cicloheptílicos como antagonistas de LPA |
| KR20210060546A (ko) * | 2018-09-18 | 2021-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| WO2020060915A1 (en) | 2018-09-18 | 2020-03-26 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
| CN113260310A (zh) * | 2018-10-15 | 2021-08-13 | 百时美施贵宝公司 | 用于成像lpa1受体的放射性配体 |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| MX2021012357A (es) * | 2019-04-16 | 2021-11-04 | Bristol Myers Squibb Co | Proceso para preparar compuestos de acido carbamoiloximetil triazol ciclohexilico. |
| KR20220024548A (ko) | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 트리아졸 카르복실산 |
| JP7422788B2 (ja) | 2019-06-18 | 2024-01-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのイソキサゾールカルボン酸 |
| US20220235027A1 (en) | 2019-06-18 | 2022-07-28 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
| JP7173350B2 (ja) | 2019-07-30 | 2022-11-16 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物 |
| CN114728168B (zh) * | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | ***氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| WO2021107125A1 (ja) * | 2019-11-29 | 2021-06-03 | 小野薬品工業株式会社 | リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途 |
| CA3157595A1 (en) | 2019-12-12 | 2021-06-17 | Gabriele Amari | Thienopyrimidine derivatives as lpa receptor 2 inhibitors |
| JP2023505703A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としての芳香族アミド誘導体 |
| US20230063121A1 (en) | 2019-12-12 | 2023-03-02 | Chiesi Farmaceutici S.P.A. | Quinazoline derivatives as lpa receptor 2 inhibitors |
| CN111195254B (zh) * | 2020-02-25 | 2021-03-16 | 中国医学科学院阜外医院 | Lpa2及其激动剂的应用 |
| KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202344504A (zh) | 2020-06-03 | 2023-11-16 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CA3185111A1 (en) | 2020-07-16 | 2022-01-20 | Elisabetta Armani | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| EP4232431A1 (en) * | 2020-10-22 | 2023-08-30 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
| WO2022100625A1 (zh) * | 2020-11-10 | 2022-05-19 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| CN114456147A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氧取代氨基碳酸酯噻吩类化合物 |
| CN114456159A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氮取代杂环噻吩类化合物及其用途 |
| CN114621135B (zh) * | 2020-12-11 | 2024-01-30 | 上海拓界生物医药科技有限公司 | 一种lpa1小分子拮抗剂 |
| CN112778187B (zh) * | 2021-01-06 | 2022-10-28 | 烟台舜康生物科技有限公司 | 一种海那替尼中间体的合成方法及所得的海纳替尼中间体 |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| CN117043144A (zh) | 2021-03-24 | 2023-11-10 | 奇斯药制品公司 | 作为lpa受体2抑制剂的8-环-取代的喹唑啉衍生物 |
| JPWO2022270621A1 (hr) * | 2021-06-25 | 2022-12-29 | ||
| WO2023001177A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海拓界生物医药科技有限公司 | 一种lpa1小分子拮抗剂 |
| WO2023066359A1 (en) * | 2021-10-21 | 2023-04-27 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN116640117A (zh) * | 2021-12-15 | 2023-08-25 | 武汉人福创新药物研发中心有限公司 | 三氮唑类lpar1拮抗剂及其用途 |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| WO2023170025A1 (en) | 2022-03-08 | 2023-09-14 | Chiesi Farmaceutici S.P.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| WO2023178061A1 (en) | 2022-03-15 | 2023-09-21 | Bristol-Myers Squibb Company | Biocatalytic synthesis of (1s,3s)-3-hydroxycyclohexane-1-carboxylic acid compounds |
| CN117024409A (zh) * | 2023-10-10 | 2023-11-10 | 药康众拓(北京)医药科技有限公司 | 氘代lpa1抑制剂化合物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1695422A (en) | 1928-12-18 | A cobpobation | ||
| US1695432A (en) | 1924-03-18 | 1928-12-18 | Arthur W Lovejoy | Toilet-paper holder |
| US1695455A (en) | 1925-12-07 | 1928-12-18 | Delpech Jacques | Apparatus for the manufacture of artificial filaments |
| US1677284A (en) | 1926-04-23 | 1928-07-17 | Goodrich Co B F | Sheet material and method of making and mounting the same |
| US1695431A (en) | 1926-10-05 | 1928-12-18 | Fred H Linley | Combustion control in steam-boiler furnaces |
| GB267434A (en) | 1926-11-12 | 1927-03-17 | Thomas Whyte Guthrie | An improved billiard-cue tip |
| US1695454A (en) | 1927-05-23 | 1928-12-18 | Edward J Coyne | Door spring |
| IT1237793B (it) | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
| WO2002062389A1 (fr) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
| JP2007523178A (ja) | 2004-02-18 | 2007-08-16 | アストラゼネカ アクチボラグ | 代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用 |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| JP5919291B2 (ja) | 2010-11-09 | 2016-05-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｇａｂａ受容体リガンドとしてのトリアゾール誘導体 |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| SG190417A1 (en) | 2010-12-07 | 2013-07-31 | Amira Pharmaceuticals Inc | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis |
| CN103443098B (zh) * | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
| WO2012137982A2 (en) | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2013085824A1 (en) * | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| MX2014014710A (es) | 2012-06-20 | 2015-03-04 | Hoffmann La Roche | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). |
| KR20150011389A (ko) | 2012-06-20 | 2015-01-30 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서 n-아릴트라이아졸 화합물 |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| AR108838A1 (es) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| AR108745A1 (es) | 2016-06-21 | 2018-09-19 | Syngenta Participations Ag | Derivados de oxadiazol microbiocidas |
| CN112074515A (zh) | 2017-12-19 | 2020-12-11 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| PT3710438T (pt) | 2017-12-19 | 2021-11-22 | Bristol Myers Squibb Co | Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa |
| WO2019126089A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| WO2019126098A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| WO2019126099A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| JP7301839B2 (ja) | 2017-12-19 | 2023-07-03 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 |
| US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| JP7212047B2 (ja) | 2017-12-19 | 2023-01-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
-
2017
- 2017-06-19 AR ARP170101698A patent/AR108838A1/es unknown
- 2017-06-20 CA CA3029202A patent/CA3029202C/en active Active
- 2017-06-20 ME MEP-2020-141A patent/ME03804B/me unknown
- 2017-06-20 WO PCT/US2017/038216 patent/WO2017223016A1/en unknown
- 2017-06-20 PT PT201546512T patent/PT3666771T/pt unknown
- 2017-06-20 DK DK17734594.9T patent/DK3472148T3/da active
- 2017-06-20 RS RS20211353A patent/RS62524B1/sr unknown
- 2017-06-20 MX MX2018015563A patent/MX2018015563A/es unknown
- 2017-06-20 CN CN202210167783.7A patent/CN114601830A/zh active Pending
- 2017-06-20 UY UY0001037302A patent/UY37302A/es active IP Right Grant
- 2017-06-20 DK DK20154651.2T patent/DK3666771T3/da active
- 2017-06-20 TW TW110110259A patent/TWI757128B/zh active
- 2017-06-20 SI SI201730979T patent/SI3666771T1/sl unknown
- 2017-06-20 BR BR112018076558-9A patent/BR112018076558A2/pt active Search and Examination
- 2017-06-20 JP JP2018566914A patent/JP7073281B2/ja active Active
- 2017-06-20 EP EP17734594.9A patent/EP3472148B1/en active Active
- 2017-06-20 TW TW106120551A patent/TWI725200B/zh active
- 2017-06-20 SG SG11201811321TA patent/SG11201811321TA/en unknown
- 2017-06-20 LT LTEP17734594.9T patent/LT3472148T/lt unknown
- 2017-06-20 US US15/628,104 patent/US10071078B2/en not_active Ceased
- 2017-06-20 ES ES20154651T patent/ES2895385T3/es active Active
- 2017-06-20 PL PL20154651T patent/PL3666771T3/pl unknown
- 2017-06-20 CN CN201780050555.9A patent/CN109963843B/zh active Active
- 2017-06-20 EP EP20154651.2A patent/EP3666771B1/en active Active
- 2017-06-20 AU AU2017281439A patent/AU2017281439B2/en active Active
- 2017-06-20 EA EA201892710A patent/EA037585B1/ru not_active IP Right Cessation
- 2017-06-20 PE PE2018003307A patent/PE20190211A1/es unknown
- 2017-06-20 RS RS20200603A patent/RS60347B1/sr unknown
- 2017-06-20 KR KR1020197001470A patent/KR102377340B1/ko active IP Right Grant
- 2017-06-20 HU HUE17734594A patent/HUE049944T2/hu unknown
- 2017-06-20 SI SI201730240T patent/SI3472148T1/sl unknown
- 2017-06-20 ES ES17734594T patent/ES2785951T3/es active Active
- 2017-06-20 MY MYPI2018002672A patent/MY195782A/en unknown
- 2017-06-20 KR KR1020227008719A patent/KR102463621B1/ko active IP Right Grant
- 2017-06-20 HU HUE20154651A patent/HUE057211T2/hu unknown
- 2017-06-20 HR HRP20211708TT patent/HRP20211708T8/hr unknown
- 2017-06-20 PT PT177345949T patent/PT3472148T/pt unknown
- 2017-06-20 LT LTEP20154651.2T patent/LT3666771T/lt unknown
- 2017-06-20 PL PL17734594T patent/PL3472148T3/pl unknown
-
2018
- 2018-07-18 US US16/038,739 patent/US10576062B2/en active Active
- 2018-12-17 IL IL263767A patent/IL263767B/en unknown
- 2018-12-19 ZA ZA2018/08580A patent/ZA201808580B/en unknown
- 2018-12-20 CL CL2018003708A patent/CL2018003708A1/es unknown
-
2019
- 2019-01-17 CO CONC2019/0000471A patent/CO2019000471A2/es unknown
-
2020
- 2020-01-02 US US16/732,387 patent/US11007180B2/en active Active
- 2020-04-13 HR HRP20200586TT patent/HRP20200586T1/hr unknown
- 2020-06-10 CY CY20201100531T patent/CY1123443T1/el unknown
- 2020-09-03 US US17/011,592 patent/USRE49352E1/en active Active
-
2021
- 2021-04-05 US US17/221,859 patent/US20210244711A1/en not_active Abandoned
- 2021-07-30 AU AU2021209334A patent/AU2021209334B2/en active Active
- 2021-11-19 CY CY20211101007T patent/CY1124737T1/el unknown
-
2022
- 2022-04-12 US US17/718,760 patent/US20220249443A1/en not_active Abandoned
- 2022-05-11 JP JP2022078334A patent/JP7312295B2/ja active Active
-
2023
- 2023-08-22 US US18/453,431 patent/US20230390249A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211708T1 (hr) | Antagonisti lpa | |
| JP2019518766A5 (hr) | ||
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| HRP20192209T1 (hr) | Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini | |
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2021508686A5 (hr) | ||
| HRP20170404T1 (hr) | SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA | |
| HRP20211542T1 (hr) | Tetrasupstituirani spojevi alkena i njihova uporaba | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| BR112014027190A2 (pt) | pirrolobenzodiazepinas | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| HRP20100541T1 (hr) | Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2016506960A5 (hr) | ||
| JP2016534134A5 (hr) | ||
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| JP2017132814A5 (hr) | ||
| PH12020550921A1 (en) | Cap-dependent endonuclease inhibitors | |
| AR081626A1 (es) | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos | |
| RU2014149183A (ru) | Проницаемые ингибиторы гликозидазы и их применения | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| RS54708B1 (en) | ARYLETINYL DERIVATIVES | |
| RS54165B1 (en) | NEW LIGANDS FOR THE ESTROGENIC RECEPTOR | |
| RS54518B1 (en) | Bicyclic Heterocyclic Compounds as Protein Tyrosine Kinase Inhibitors |